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Neuronal death induced by overactivation of N-methyl-d-aspartate receptors (NMDARs)
is implicated in the pathophysiology of many neurodegenerative diseases such as stroke,
epilepsy and traumatic brain injury. This toxic effect is mainly mediated by NR2B-containing
extrasynaptic NMDARs, while NR2A-containing synaptic NMDARs contribute to cell
survival, suggesting the possibility of therapeutic approaches targeting specific receptor
subunits. We report that fractalkine/CX3CL1 protects hippocampal neurons from NMDA-
induced cell death with a mechanism requiring the adenosine receptors type 2A (A2AR).
This is different from CX3CL1-induced protection from glutamate (Glu)-induced cell death,
that fully depends on A1R and requires in part A3R. We show that CX3CL1 neuroprotection
against NMDA excitotoxicity involves D-serine, a co-agonist of NR2A/NMDAR, resulting in
cyclic AMP-dependent transcription factor cyclic-AMP response element-binding protein
(CREB) phosphorylation.
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INTRODUCTION
Neuroprotection is a complex procedure aimed at preserva-
tion of neuronal structure and function upon toxic insults.
Glutamate (Glu)-induced excitotoxicity is one of the most
important mechanism known to trigger cell death in CNS dis-
orders: over-excitation of Glu receptors, principally N-methyl-
d-aspartate receptors (NMDARs), allows for an uncontrolled
increase of intracellular Ca2+ and the dysregulation of intra-
cellular pathways leading to cell death (Sattler and Tymianski,
2000, 2001). Nevertheless, depending on the receptor subtype
involved, NMDA stimulation may exert protective effects. Low
levels of Glu activate NMDARs in preconditioning experiments
(Liu et al., 2009), resulting protective against a subsequent
stronger insult. This is achieved through multifactorial mecha-
nisms involving the rapid adaptation of the voltage-dependent
Ca2+ channels (Shimazaki et al., 1998), the release of brain
derived neurotropic factor (BDNF; Blondeau et al., 2001), the
activation of phosphatidylinositol 3-kinase (PI3K)/Akt/glycogen
synthase kinase 3-beta signaling (Hetman and Xia, 2000; Papadia
et al., 2005; Soriano et al., 2006), extracellular signal-regulated
kinase (ERK 1/2), the inactivation of c-Jun N-terminal kinase
(JNK) and cyclic-AMP response element-binding protein (CREB;
Navon et al., 2012). The NMDAR is a pentameric pro-
tein with different subunit composition that changes during
development (Monyer et al., 1994). In adulthood, NMDARs
with specific subunit composition have different cellular and
subcellular distribution in the CNS (Ikeda et al., 1992; Kutsuwada
et al., 1992; Monyer et al., 1992). In particular, NR2A and
NR2B subunits are abundantly expressed in the hippocampusd
(Monyer et al., 1994; Laurie et al., 1997) with a prefer-
ential extrasynaptic localization of NR1/NR2B and a synap-
tic localization of NR1/NR2A/NR2B in the forebrain (Stocca
and Vicini, 1998; Tovar and Westbrook, 1999; Thomas et al.,
2006). Several studies demonstrated that NMDAR localization
correlates with opposite functions: extrasynaptic NMDARs are
linked to damage-induced toxicity while synaptic NMDARs
provide neuroprotection (Chen et al., 2008; Hardingham and
Bading, 2010), activating neuroprotective pathways such as
Akt, ERK1/2 (Hardingham et al., 2001a; Papadia et al., 2005;
Wang et al., 2013), and CREB (Hardingham et al., 2001b,
2002). NMDAR functions are known to be modulated by co-
factors such as glycine and D-serine (Johnson and Ascher,
1987; Matsui et al., 1995). While glycine preferentially acts
on extrasynaptic NMDARs, D-serine binds with higher affin-
ity to synaptic NMDARs (Madry et al., 2007; Papouin et al.,
2012). We have previously shown that fractalkine/CX3CL1
modulates NMDA-mediated synaptic transmission in the hip-
pocampal CA1 region through the activity of the adenosine
receptors type 2A (A2AR) and the release of D-serine from glia
(Scianni et al., 2013). Since it is known that CX3CL1 is able
to counteract excitotoxic damage (Deiva et al., 2004; Limatola
et al., 2005) in the present paper we investigated the effects of
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CX3CL1 on NMDA-mediated neurotoxicity and demonstrated
that CX3CL1 is neuroprotective with mechanisms requiring the




Recombinant human CX3CL1 was from Calbiochem/Merck
(Nottingham, UK); D-serine was from Ascent Scientific (Bris-
tol, UK); rabbit anti-phospho TrkB (Tyr 515) was from
Abcam (Cambridge, UK), rabbit anti-phospo CREB (Ser 133)
and rabbit anti-PARP were from Cell Signaling (Danvers,
Ma, USA); secondary antibodies were from DAKO (Milan,
Italy); culture media were from Invitrogen Life Technologies
(San Giuliano Milanese, Italy); 3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT), in vitro Toxicology Assay
Kit Lactic Dehydrogenase based (LDH assay), catalase, D-amino
acid oxidase (DAAO), poly-L-lysine, rabbit anti-actin antibody
and all the other reagents were from Sigma-Aldrich (Milan,
Italy).
ANIMALS AND CELL LINES
Procedures using laboratory animals were in accordance with
the international guidelines on the ethical use of animals from
the European Communities Council Directive of 24 November
1986 (86/609/EEC). A1R−/− (Johansson et al., 2001) A2AR−/−
(Chen et al., 1999) and A3R−/− (Salvatore et al., 2000) mice were
backcrossed at least 10 times on a C57BL/6 background.
HIPPOCAMPAL NEURONAL CULTURES
Primary hippocampal neuronal cultures were prepared from
0–2-day-old (p0–p2) C57BL/6 (WT), A1R−/−, A2AR−/− and
A3R−/− mice. Briefly, after careful dissection from diencephalic
structures, the meninges were removed and hippocampal tissues
chopped and digested for 20 min at 37◦C in 0.025% trypsin
and Hank’s balanced salt solution (HBSS). Cells were washed
twice with HBSS to remove the excess of trypsin, mechanically
dissociated in minimal essential medium (MEM) with Earl’s Salts
and GLUTAMAX supplemented with 10% dialyzed and heat
inactivated fetal bovine serum (FBS), 100 µg/ml gentamycin, and
25 mM KCl. Cells were plated at a density of 2 × 105 in the
same medium on poly-L-lysine (100 mg/ml)-coated plastic 24-
well dishes. After 1–2 h, the medium was replaced with serum-
free Neurobasal/B27. Cells were kept at 37◦C in 5% CO2 for
11–12 days with twice a week medium replacement (1:1 ratio).
At this time point we have 2 × 105 ± 0.05 × 105 alive cells
(which corresponds to about 85% of initially plated cells); no
significant differences were obtained in the number of living cells
in hippocampal preparations obtained from the brains of WT
and genetically modified mice. With this method we obtained
60–70% neurons, 30–35% astrocytes, 4–8% microglia, as deter-
mined with β-tubulin III, GFAP, and IBA-I staining (Lauro et al.,
2010).
EXCITOTOXICITY EXPERIMENTS
Before stimulation, medium conditioned by cultured cells was
removed and stored for later use. To induce excitotoxicity,
hippocampal neuronal cultures were stimulated in Locke’s buffer
(in mM: 154 NaCl, 5.6 KCl, 3.6 NaHCO3, 5 HEPES, 2.3 CaCl2,
5,6 glucose, 10 glycine pH 7.4) with 100 µM Glu or 200 µM
NMDA alone or together with 100 nM CX3CL1 or D-serine
at different concentrations (from 10 nM to 10 µM) or vehi-
cle, for 30 min. For excitotoxicity experiments with DAAO
hippocampal cultures were pretreated with DAAO (0.1 U/ml)
and catalase (300 U/ml) for 1 h and then stimulated with
Glu (100 µM) or NMDA (200 µM) in the presence or in
the absence of CX3CL1 100 nM or D-serine 100 nM. Fol-
lowing stimulation, cells were washed in Locke’s buffer and
re-incubated in the previously stored conditioned medium for
additional 16 h. Under these experimental conditions Glu and
NMDA induced about 40–50% of cell death in comparison
with untreated control cultures. This corresponds to about 70%
of neuronal death (Lauro et al., 2010) for necrotic and apop-
totic processes (Bonfoco et al., 1995; Nicotera et al., 1999).
To evaluate neuron viability cells were treated with detergent-
containing buffer (0.05% ethyl hexadecyl dimethylammonium
bromide, 0.028% acetic acid, 0.05% Triton X-100, 0.3 mM NaCl,
0.2 mM MgCl2, in PBS pH 7.4) and the remaining nuclei
were counted in a hemacytometer, as already described (Volontè
et al., 1994). In all figures data were expressed as percentage
of viable cells taking as 100% those present in control con-
ditions. To evaluate viability, cells were also analyzed by the
MTT assay: in detail, 5 mg/mL MTT was added 1:10 to the
cell medium and incubated for 2 h at 37◦C; the medium was
aspired, cells were treated with DMSO and incubated at 37◦C for
10 min. Samples were then analyzed with a microplate reader at
490 nm and 630 nm to subtract background. Data were expressed
as % of cell viability, taking as 100% viability in untreated
cells.
LDH ACTIVITY
To measure in vitro citotoxicity due to NMDA, released LDH
was measured by LDH assay kit (SIGMA) according to manifac-
ture procedure. Data were expressed as % of extracellular LDH
activity in treated cells (NMDA or NMDA/CX3CL1) vs. untreated
cells.
WESTERN BLOT ANALYSIS
Hippocampal neuronal cultures were plated at a density of
2 × 105 on poly-L-lysine (100 mg/ml)-coated plastic 24-well
dishes, incubated for 2 h in Locke’s buffer and stimulated
for 15 min with CX3CL1 (100 nM), D-serine (100 nM) or
vehicle and analyzed for CREB and TrkB phosphorylation.
In some experiments hippocampal cultures were pretreated
with DAAO (0.1 U/ml) and catalase (300 U/ml) for 1 h.
For PARP analysis, hippocampal cultures were stimulated in
Locke’s buffer for 30 min with NMDA (200 µM) alone or
together with CX3CL1 (100 nM), washed, re-incubated in
the previously stored conditioned medium and lysed after 16
h for western blot experiments. For each condition, equal
amounts of proteins were loaded on SDS-polyacrylamide
gel, band intensity was normalized for actin and densito-
metric analyses were performed with QuantityOne software
(Biorad).
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RNA EXTRACTION AND ANALYSIS FOR BDNF
Total RNA from primary hippocampal cultures (2.5 × 105
cells) was extracted by Trizol reagent (Invitrogen). Reverse
transcription reaction was performed in a thermocycler (MJ
Mini Personal Thermal Cycler; Biorad) using IScript TM
Reverse Transcription Supermix (Biorad; Milan, Italy) accord-
ing to the manufacturer’s protocol. Real-time PCR (RT-PCR)
was carried out in a I-Cycler IQ Multicolor RT-PCR Detec-
tion System (Biorad) using SsoFast EvaGreen Supermix (Bio-
rad) according to the manufacturer’s instructions. The PCR
protocol consisted of 40 cycles of denaturation at 95◦C for
30 s and annealing/extension at 58◦C for 30 s. For quantifi-
cation analysis the comparative Threshold Cycle (Ct) method
was used. The Ct values from bdnf gene were normal-
ized to the Ct value of Gapdh in the same RNA sam-
ples. Relative quantification was performed using the 2−∆∆Ct
method (Schmittgen and Livak, 2008) and expressed as fold
change in arbitrary values. Primer sequences targeted against
mouse BDNF and mouse GAPDH were as follows: bdnf 5’-
TGAGTCTCCAGGACAGCAAA-3’ (F); 5’-TGTCCGTGGACGTT
TACTTCT-3’ (R); gapdh 5’-TCGTCCCGTAGACAAAATGG-3’
(F); 5’-TTGAGGTCAATGAAGGGGTC-3’ (R).
MEASUREMENT OF BDNF BY ELISA
Hippocampal cultures were stimulated with CX3CL1 (100 nM)
for 5, 30, 60 and 180 min and lysed with an ELISA lysis buffer
(137 mM NaCl, 20 mM Tris-HCl, 1% NP40, 10% glycerol, 1 mM
PMSF, 10 mg/ml aprotinin, 1 mg/ml leupeptin and 0.5 mM
sodium vanadate). The cell debris were centrifuged and the
supernatant was collected and analyzed for BDNF concentration
(ng/ml) using the BDNF EMAX ImmunoAssay System (Promega;
Madison, Wi, USA). The ELISA was performed according to the
manufacturer’s instructions.
STATISTICAL DATA ANALYSIS
Data are shown as the mean ± SEM; appropriate Student’s t-test
or analysis of variance (ANOVA) were used as specified in figure
legends. The significant differences between groups of data were
specified in each figure legend. All statistical analysis was done
using Sigma Plot 11.0 software.
RESULTS
CX3CL1 NEUROPROTECTION AGAINST NMDA REQUIRES A2AR
CX3CL1 is neuroprotective against Glu-induced excitotoxicity,
with mechanisms fully dependent on A1R (Lauro et al., 2008,
2010) and in part dependent on A3R (Rosito et al., 2014).
CX3CL1 also protects neurons against NMDA-induced death
(Deiva et al., 2004), but no evidence of ARs involvement are
reported so far. For this reason we performed experiments
on the neuroprotective effects of CX3CL1 against NMDA-
and Glu-induced excitotoxicity in primary hippocampal cul-
tures. Data reported in Figure 1A confirms that CX3CL1
has similar protective effects both against NMDA (200 µM,
30 min) and Glu (100 µm, 30 min) (n = 6–13; p ≤ 0.05).
CX3CL1 neuroprotective effect was also confirmed by MTT
assay, being cell viability 57.6 ± 2.6% of control upon NMDA
treatment (p ≤ 0.05) and rising to 91.6 ± 3% of control
FIGURE 1 | Neuroprotective effect of CX3CL1 against NMDA toxic
insult requires A2AR. (A) Glu- and NMDA-excitotoxic experiments were
performed in mouse hippocampal cultures in the presence or in the
absence of CX3CL1 (n = 6–13). (B) Western blot analysis for PARP (cleaved
and uncleaved PARP) in NMDA, NMDA/CX3CL1 and CX3CL1 treated
hippocampal cells. Representative blots are shown on top. Data are
expressed as % of cleaved/uncleaved PARP vs. untreated cells (C) (n = 3).
(C) NMDA-excitotoxic experiments were performed in hippocampal
cultures from WT, A1R−/−, A2AR−/− and A3R−/− mice treated or not with
CX3CL1(n = 5–10). In (A) and (C) data are expressed as percentage of cell
survival taking as 100% the number of viable cells in control condition (C).
Results represent the mean ± SEM. Statistical analysis: one-way ANOVA
followed by Dunn’s post hoc test *p ≤ 0.05 (A); one-way ANOVA followed
by Holm-Sidak post hoc test *p ≤ 0.05 (B, C).
upon NMDA/CX3CL1 costimulation (n = 3; One way Anova
followed by Holm-Sidak post hoc test). Similar results were
obtained measuring cell death by LDH release: increasing
to 139.4 ± 6.9% of control upon NMDA treatment (p ≤
0.05) and being 104.4 ± 3.5% of control in NMDA/CX3CL1
treated cells (n = 3; One way Anova followed by Holm-
Sidak post hoc test). To evaluate the contribution of apop-
totic pathways, we analyzed the level of PARP cleavage and
found that although a partial reduction between NMDA and
NMDA/CX3CL1 treated cells was observed, it was not statistical
significant (Figure 1B). All together these results are in line
with the observation that both necrosis and apoptosis contribute
to excitotoxic neuronal death (Bonfoco et al., 1995; Nicotera
et al., 1999) and suggest that CX3CL1 plays effects on both
pathways.
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To evaluate the involvement of ARs in CX3CL1-mediated pro-
tection against NMDA, experiments were performed in primary
hippocampal cultures from A1R−/−, A2AR−/− and A3R−/− mice.
Results shown in Figure 1C demonstrate that the CX3CL1 pro-
tective effect was lost only in cell cultures lacking A2AR (n = 5–10;
p ≤ 0.05).
EXTRACELLULAR D-SERINE MEDIATES CX3CL1 NEUROPROTECTION
AGAINST NMDA
We have recently demonstrated that CX3CL1 induces D-serine
release by glial cells and that both D-serine and A2AR are necessary
for CX3CL1-mediated potentiation of synaptic NMDAR function
(Scianni et al., 2013). To investigate the possible involvement
of D-serine in the neuroprotective effects of CX3CL1, excito-
toxicity experiments were performed in the presence of DAAO
(0.1 U/ml) and catalase (300 U/ml), to remove extracellular
serine and the hydrogen peroxide by-products, respectively. Data
reported in Figure 2 show that DAAO/catalase treatment (DAAO)
efficiently inhibited the protective effects of CX3CL1 against
NMDA-induced cell death (n = 9; p ≤ 0.05; Figure 2A), being
ineffective on Glu-excitotoxicity (n = 6; p ≤ 0.05; Figure 2B).
We also tested the ability of D-serine to promote neuropro-
tection against excitotoxicity: as reported in Figure 2C, upon
NMDA challenge D-serine induced neuroprotection in a dose
dependent way (n = 5–15; p ≤ 0.05) while it was ineffective in
counteracting the effect of Glu challenge (n = 6–9; p ≤ 0.05
Figure 2D).
CX3CL1 AND D-SERINE INDUCE CREB PHOSPHORYLATION REQUIRING
THE EXPRESSION OF A2AR
Hippocampal neuronal cultures were treated with CX3CL1 or
D-serine for 15 min and analyzed for CREB phosphoryla-
tion. Data reported in Figures 3A,B demonstrate that both
CX3CL1 and D-serine significantly increased CREB phos-
phorylation (n = 5; ∗∗p ≤ 0.001) and that DAAO/catalase
treatment significantly reduced it (n = 5 ∗p ≤ 0.05 and
∗∗p ≤ 0.001).
Since it is known that NMDARs are able to modulate BDNF
expression through CREB signaling (Hardingham et al., 2002;
Jiang et al., 2005) we analyzed BDNF gene and protein expres-
sion upon CX3CL1 treatment. Data obtained indicate that both
mRNA and protein BDNF levels were increased upon CX3CL1
treatment, with different kinetics. mRNA levels reach a peak at
15 min (2.7 ± 0.5 fold; n = 3; p ≤ 0.05) and are maintained
up to 180 min (2.3 ± 0.4 fold; n = 3; p ≤ 0.05, One way
Anova followed by Holm-Sidak post hoc test). BDNF protein
is significantly increased after 60 min of CX3CL1 stimulation
(time 0: 229.4 ± 1 pg/ml; 60 min: 754.5 ± 32 pg/ml; n = 3;
p ≤ 0.05, One way Anova followed by Holm-Sidak post hoc
test) and returns to basal values after 180 min (231.2 ± 9.6
pg/ml). Moreover we also observed that after 15 min of CX3CL1
stimulation there is an increase in TrkB phosphorylation (1.8 ±
0.3 fold; n = 3; p ≤ 0.05, One-way ANOVA followed by Dunn’s
post hoc test).
Experiments were performed to evaluate the role of A2ARs
in CX3CL1- and D-serine-mediated CREB phosphorylation.
At this aim hippocampal neuronal cultures from A2AR−/−
FIGURE 2 | D-serine contributes to CX3CL1 neuroprotection against
NMDA toxic insult. (A) NMDA- or (B) Glu-excitotoxic experiments were
performed in mouse hippocampal cultures pretreated or not with
DAAO/catalase (DAAO) and stimulated or not with CX3CL1 (n = 9 and n = 6
respectively). Data are expressed as percentage of cell survival in treated
vs. untreated cultures (C) without DAAO. Results represent the mean ±
SEM. Statistical analysis: one-way ANOVA followed by Holm-Sidak post hoc
test *p ≤ 0.05 (A); one-way ANOVA followed by Dunn’s post hoc test *p ≤
0.05 (B). (C) NMDA- or (D) Glu-excitotoxic experiments were performed in
mouse hippocampal cultures treated or not with D-serine, at the indicated
concentration (n = 5–15 and n = 6–9 respectively). Data are expressed as
percentage of cell survival in treated vs. C cultures without DAAO. Results
represent the mean ± SEM. Statistical analysis: one-way ANOVA followed
by Dunn’s post hoc test *p ≤ 0.05 (C); one-way ANOVA followed by
Holm-Sidak post hoc test *p ≤ 0.05 (D).
mice were treated with CX3CL1 or D-serine for 15 min
and analyzed for CREB phosphorylation. Interestingly, in the
absence of A2AR, neither CX3CL1 nor D-serine were able
to induce CREB phosphorylation (n = 7; Figure 3C). In
order to understand if A2AR could play a role in mediating
the neuroprotective effect of D-serine against NMDA-induced
excitotoxicity, experiments were performed on A2AR−/− hip-
pocampal cultures in the presence of D-serine (100 nM).
Results shown in Figure 4 demonstrated that in absence of
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FIGURE 3 | CX3CL1 and D-serine induce CREB phosphorylation
requiring the expression of A2AR. (A) Mouse hippocampal cultures,
pretreated or not with DAAO/catalase (DAAO), were analyzed by
western blot for phospho-CREB (p-CREB) and actin upon CX3CL1 or
(B) D-serine stimulation. Representative blots are shown on top. Data,
expressed as % of p-CREB vs. C and normalized on actin, represent
the mean ± SEM of 5 independent experiments. Statistical analysis:
Student’s t-test **p ≤ 0.001 and one-way ANOVA followed by
Holm-Sidak post hoc test *p ≤ 0.05 (A); Student’s t-test **p ≤ 0.001
and one-way ANOVA followed by Dunn’s post hoc test **p ≤ 0.001
(B). (C) Hippocampal cultures from A2AR−/− mice were analyzed by
western blot for phospho-CREB and actin upon CX3CL1 or D-serine
stimulation. Data, expressed as % of p-CREB vs. C and normalized on
actin, represent the mean ± SEM of 5 independent experiments.
the A2AR, D-serine has no neuroprotective effects (n = 10;
p ≤ 0.05).
DISCUSSION
NMDARs are versatile receptors modulating physiological and
pathological activities in the nervous system. They are involved
in development, synapse maturation, synaptic transmission and
plasticity processes, and their dysfunction has been impli-
cated in several neurodegenerative diseases and mood disor-
ders (Malenka and Bear, 2004; Hardingham and Bading, 2010;
Zhou and Sheng, 2013; Ghasemi et al., 2014). NMDAR stim-
ulation may induce neuronal death (Choi, 1987; Choi et al.,
1988; Tymianski et al., 1993) or protection, also through pre-
conditioning (Grabb and Choi, 1999; Navon et al., 2012).
This apparently dicothomic behavior of NMDARs has been
in part ascribed to their synaptic or extrasynaptic localization
(Ikonomidou and Turski, 2002; Hardingham, 2006; Hetman and
Kharebava, 2006), corresponding to different subunit composi-
tion (Hardingham et al., 2002; Chen et al., 2008). While synaptic
NR2A/NMDARs are involved in protective mechanisms, extrasy-
naptic, NR2B/NMDARs preferentially lead to the activation of
death pathways (Hardingham and Bading, 2010). D-serine is a
preferential co-agonist of NR2A-containing NMDARs, and we
wanted to verify the hypothesis that it could be involved in
CX3CL1-induced neuroprotective effects. Although in vitro sys-
tems do not allow to distinguish between synaptic and extrasy-
naptic NMDAR, cultured hippocampal neurons do express both
NR2A and NR2B subunits (Li et al., 2014) and can be used to
investigate the effects of both kinds of NMDARs. In this paper
we report data showing that: (i) NMDA-induced excitotoxic-
ity is prevented by CX3CL1 with mechanisms involving A2AR;
(ii) D-serine mediates the neuroprotective effect of CX3CL1
against NMDA- but not Glu-toxicity; (iii) CX3CL1 and D-serine
phosphorylate CREB with a mechanism involving the presence of
A2AR. Adenosine is a metabolite that acts through different recep-
tor subtypes (Jacobson and Gao, 2006); among them A1R (Lauro
et al., 2008, 2010) and A3R (Rosito et al., 2014) are involved in
CX3CL1 neuroprotection against Glu-induced toxicity. Moreover
we previously demonstrated that CX3CL1 triggers the release
of adenosine from neuronal and microglial cells (Lauro et al.,
2008, 2010). In this paper we demonstrate that upon NMDA-
induced toxicity, the protective effects of CX3CL1 specifically
requires A2AR expression and the presence of D-serine. These
results are in line with the data showing that both CX3CL1-
induced modulation of NMDA fEPSP and D-serine release from
glial cell require A2AR (Scianni et al., 2013). Together these data
suggest a mechanism where the protective effects of CX3CL1 are
mediated by the activation and the expression of A2AR and conse-
quentially the D-serine-dependent activation of NR2A/NMDARs.
CX3CL1 modulates NMDAR effects, in an A2AR-dependent way,
potentiating neurotransmission and increasing NR2A/NMDAR
protective effects, likely shifting the balance of NMDAR acti-
vation toward NR2A-containing, D-serine-sensitive NMDARs.
Nevertheless we cannot exclude that other pathways triggered by
CX3CL1 act synergistically with A2AR: we showed indeed that
CX3CL1 increases BDNF expression and TrkB phosphorylation,
events possibly linked to CREB phosphorylation (Pizzorusso
et al., 2000; Lee et al., 2005) thus explaining the partial block
of CREB phosphorylation when D-serine is degraded by DAAO.
We also speculate that at least part of the protective effects
of CX3CL1 against NMDA could be due to A2AR-dependent
intracellular pathways contrasting NMDA-mediated toxicity that
do not depend on D-serine. Indeed, in addition to play a sig-
nificant role in D-serine release, A2AR directly contributes to
NR2A/NMDAR potentiation as shown by the observation that
D-serine alone is not sufficient to induce neuroprotection or
CREB phosphorylation in A2AR−/− hippocampal cultures. These
data may suggest that A2AR also acts downstream of D-serine,
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FIGURE 4 | A2AR mediates the neuroprotective effect of D-serine
against NMDA-induced excitotoxicity. NMDA-excitotoxic experiments
were performed in hippocampal cultures from A2AR−/− mice treated or not
with CX3CL1 (n = 12) or D-serine (n = 10). Data are expressed as cell
survival vs. C. Results represent the mean ± SEM. Statistical analysis:
one-way ANOVA followed by Dunn’s post hoc test *p ≤ 0.05.
regulating the activity of NMDAR independently of D-serine. It
should be considered that different populations of A2AR have
different localization and functions, with those expressed by glial
cells mostly responsible for the release of D-serine and those
expressed post-synaptically modulating NMDARs activity. In line
with this hypothesis, it has been reported that A2ARs colocal-
ize post-synaptically with metabotropic Glu receptors, playing
a permissive role in mGluR5-mediated potentiation of NMDA
in the hippocampus (Tebano et al., 2005). Alternatively A2AR
could have a role in modulating NMDAR subunit phospho-
rylation, since NMDAR functions are known to be modulated
by phosphorylation upon G-protein-coupled receptor activation
(Köles et al., 2001). Our data suggest a functional interac-
tion of NMDAR with A2AR, as shown in Huntington’s disease
(Martire et al., 2010) and ischemia (Yang et al., 2013). The
activation of A2AR induces the release of D-serine which acts
on NR2A/NMDARs contributing to the enhancement of “CREB
on” activation pathway (Hardingham and Bading, 2010). Part
of the A2AR-mediated effect, however, is D-serine independent,
and merits further investigation in this system. This is the first
demonstration of a functional interaction between NMDAR and
A2AR aimed at modulating protective effects: our data suggest the
hypothesis that neuronal death induced by NMDAR activation
could be counterbalanced by the selective activation (or potentia-
tion) of synaptic, D-serine sensitive NR2A/ NMDARs, providing
a possible therapeutic target for neurodegenerative pathologies.
In conclusion, we provide evidence that CX3CL1 has a broad
spectrum of protective activities against excitotoxicity induced
by Glu-receptor activation, engaging different AR subtypes
on neighboring cell types and efficiently contrasting neuronal
cell death.
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